

# Jeffrey Yap

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/146425/publications.pdf>

Version: 2024-02-01

27  
papers

3,922  
citations

279798

23  
h-index

526287

27  
g-index

27  
all docs

27  
docs citations

27  
times ranked

6385  
citing authors

#	ARTICLE	IF	CITATIONS
1	Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 495-503.	2.9	16
2	FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. <i>Cancer Imaging</i> , 2015, 15, 15.	2.8	35
3	Summary of the UPICT Protocol for <sup>18</sup> F-FDG PET/CT Imaging in Oncology Clinical Trials. <i>Journal of Nuclear Medicine</i> , 2015, 56, 955-961.	5.0	93
4	A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 113-123.	1.9	33
5	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	1.6	49
6	Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology. <i>Stat</i> , 2014, 3, 172-186.	0.4	3
7	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1202-1209.	1.6	159
8	Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 632-642.	3.4	512
9	Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. <i>Journal of Clinical Oncology</i> , 2013, 31, 3182-3190.	1.6	530
10	ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with <sup>18</sup> F-FDG PET and Correlation with Genotype and GLUT4 Expression. <i>Journal of Nuclear Medicine</i> , 2012, 53, 567-574.	5.0	49
11	Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans. <i>Radiotherapy and Oncology</i> , 2012, 102, 377-382.	0.6	21
12	Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. <i>Blood</i> , 2012, 119, 4597-4607.	1.4	278
13	Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2401-2407.	1.6	232
14	CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer. <i>Academic Radiology</i> , 2011, 18, 54-62.	2.5	83
15	Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed) Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 856-862.	1.9	99
16	New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non-Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy. <i>American Journal of Roentgenology</i> , 2010, 195, W221-W228.	2.2	182
17	Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology. <i>Clinical Cancer Research</i> , 2009, 15, 1891-1897.	7.0	54
18	Evaluation of Low-Density Neutral Oral Contrast Material in PET/CT for Tumor Imaging: Results of a Randomized Clinical Trial. <i>American Journal of Roentgenology</i> , 2009, 193, 326-332.	2.2	11

#	ARTICLE	IF	CITATIONS
19	Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 3154-3160.	1.6	295
20	F18-Fluorodeoxyglucoseâ€“Positron Emission Tomography/Computed Tomography Screening in Li-Fraumeni Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1315.	7.4	89
21	Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw. <i>Clinical Cancer Research</i> , 2008, 14, 2387-2395.	7.0	133
22	Performance Evaluation of the microPETâ€“FOCUS-F120. <i>IEEE Transactions on Nuclear Science</i> , 2007, 54, 42-49.	2.0	77
23	Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. <i>Journal of Nuclear Medicine</i> , 2006, 47, 2016-24.	5.0	25
24	Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1059-66.	5.0	522
25	Image-Guided Cancer Therapy Using PET/CT. <i>Cancer Journal (Sudbury, Mass )</i> , 2004, 10, 221-233.	2.0	66
26	Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. <i>British Journal of Cancer</i> , 2003, 89, 262-267.	6.4	61
27	Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate. <i>Journal of Clinical Oncology</i> , 2003, 21, 2823-2830.	1.6	215